RDHL — Redhill Biopharma Income Statement
0.000.00%
- $7.15m
- $2.75m
- $6.53m
- 40
- 91
- 16
- 46
Annual income statement for Redhill Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 6.29 | 64.4 | 85.8 | 61.8 | 6.53 |
Cost of Revenue | |||||
Gross Profit | 4.03 | 28.3 | 45.3 | 28.5 | 3.07 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 49.5 | 128 | 167 | 105 | -26.7 |
Operating Profit | -43.2 | -63.7 | -81.1 | -42.8 | 33.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -42.3 | -76.2 | -97.7 | -71.7 | 23.9 |
Net Income After Taxes | -42.3 | -76.2 | -97.7 | -71.7 | 23.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -42.3 | -76.2 | -97.7 | -71.7 | 23.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -42.3 | -76.2 | -97.7 | -71.7 | 23.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.142 | -0.207 | -0.191 | -0.116 | 0.001 |